Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Baseline patient characteristics

From: Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy

  ctDNA baseline All patients (n = 85) p value
Undetectable (n = 35) Detectable (n = 28)
Median age 59 (35–79) 57.5 (27–82) 57 (27–82)  
Sex
 Female 20 (57.1) 14 (50) 48 (56.5) 0.0572
 Male 15 (42.9) 14 (50) 37 (43.5)  
ECOG
 0 29 (82.9) 12 (42.9) 56 (65.9) 0.004
 1 4 (11.4) 10 (35.7) 21 (24.7)  
 2 2 (5.7) 6 (21.4) 8 (9.4)  
Mutation
 BRAF V600 E/K 24 (68.6) 22 (78.6) 63 (74) 0.374
 NRAS Q61K/R/L/H G12D G13R 11 (31.4) 6 (21.4) 22 (26)  
Stage
 III–IV1a, IV1b 11 (31.4) 3 (10.7) 18 (21.2) 0.049
 IV-M1c 24 (68.6) 25 (89.3) 67 (78.8)  
Sites ≥ 3
 No 24 (68.6) 7 (25) 38 (44.7) < 0.001
 Yes 10 (28.6) 21 (75) 45 (52.9)  
 Unknown 1 (2.9) 0 (0.0) 2 (2.4)  
Brain
 No 21 (60) 21 (75) 54 (63.5) 0.209
 Yes 14 (40) 7 (25) 31 (36.5)  
LDH
 ≤ ULN 29 (82) 9 (32.1) 46 (54.1) < 0.001
 > ULN 6 (17.1) 18 (64.3) 37 (43.5)  
 Unknown 0 (0.0) 1 (3.6) 2 (2.4)  
CRP
 ≤ ULN 22 (62.9) 9 (32.1) 38 (44.7) 0.021
 > ULN 13 (37.1) 18 (64.3) 45 (52.9)  
 Unknown 0 (0.0) 1 (3.6) 2 (2.4)  
BOR
 CR 8 (22.9) 3 (10.7) 13 (15.3)  
 PR 3 (8.6) 2 (7.1) 7 (8.2)  
 SD 6 (17.1) 3 (10.7) 15 (17.6)  
 PD 16 (46) 20 (71.4) 48 (56.5)  
 Unknown 2 (5.7) 0 (0.0) 2 (2.4)  
BRAF_MEK treatment
 Yes 20 (57.1) 18 (64.3) 51 (60) 0.693
 No 15 (42.9) 10 (35.7) 34 (40)  
  1. Absolute values are shown for each characteristic and percentages are shown between brackets, except for age where the range is shown between brackets. ULN upper limit of normal. The p value was calculated using the Fisher exact test/contingency table